{
    "hands_on_practices": [
        {
            "introduction": "ADMET models are built to predict key pharmacokinetic parameters like total drug exposure, represented by the Area Under the Curve ($AUC$), and systemic clearance ($CL$). This foundational exercise reinforces the principles behind these parameters by tasking you with deriving them from a classic one-compartment model's concentration profile . Understanding the direct link between concentration data and systemic parameters is a crucial first step for both developing and interpreting ADMET prediction models.",
            "id": "3835235",
            "problem": "Absorption, Distribution, Metabolism, Excretion, and Toxicology (ADMET) property prediction models frequently rely on fundamental pharmacokinetic relationships to estimate parameters such as clearance and exposure. Consider a one-compartment intravenous (IV) bolus dosing scenario with first-order elimination, where the plasma concentration is described by the function $C(t) = C_0 \\exp(-k t)$. You are given $C_0 = 10 \\text{ mg/L}$, $k = 0.2 \\text{ h}^{-1}$, and an administered dose of $100$ mg. Using mass balance in a single compartment and the core definitions of first-order elimination and clearance (under linear kinetics), derive and compute the total area under the concentration–time curve from zero to infinity, denoted $\\mathrm{AUC}_{0\\to\\infty}$, and the systemic clearance $\\mathrm{CL}$ for the given dose. Express the final $\\mathrm{AUC}_{0\\to\\infty}$ in mg$\\cdot$h/L and $\\mathrm{CL}$ in L/h. Round your final numerical results to four significant figures.",
            "solution": "The user wants me to solve the following problem:\nAbsorption, Distribution, Metabolism, Excretion, and Toxicology (ADMET) property prediction models frequently rely on fundamental pharmacokinetic relationships to estimate parameters such as clearance and exposure. Consider a one-compartment intravenous (IV) bolus dosing scenario with first-order elimination, where the plasma concentration is described by the function $C(t) = C_0 \\exp(-k t)$. You are given $C_0 = 10$ mg/L, $k = 0.2$ h$^{-1}$, and an administered dose of $100$ mg. Using mass balance in a single compartment and the core definitions of first-order elimination and clearance (under linear kinetics), derive and compute the total area under the concentration–time curve from zero to infinity, denoted $\\mathrm{AUC}_{0\\to\\infty}$, and the systemic clearance $\\mathrm{CL}$ for the given dose. Express the final $\\mathrm{AUC}_{0\\to\\infty}$ in mg$\\cdot$h/L and $\\mathrm{CL}$ in L/h. Round your final numerical results to four significant figures.\n\n### Step 1: Extract Givens\n-   **Pharmacokinetic model:** One-compartment intravenous (IV) bolus dosing with first-order elimination.\n-   **Plasma concentration function:** $C(t) = C_0 \\exp(-k t)$\n-   **Initial plasma concentration:** $C_0 = 10$ mg/L\n-   **First-order elimination rate constant:** $k = 0.2$ h$^{-1}$\n-   **Administered dose:** Dose $= 100$ mg\n-   **Quantities to compute:** $\\mathrm{AUC}_{0\\to\\infty}$ and systemic clearance, $\\mathrm{CL}$.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, describing a canonical model in pharmacokinetics used widely in ADMET studies. The mathematical function for concentration decay is correct for this model. The problem is well-posed, providing all necessary parameters ($C_0$, $k$, Dose) to uniquely determine the requested quantities ($\\mathrm{AUC}_{0\\to\\infty}$, $\\mathrm{CL}$). The provided values are consistent and physically realistic. For instance, the implicit volume of distribution, $V_d = \\text{Dose} / C_0 = 100 \\text{ mg} / 10 \\text{ mg/L} = 10 \\text{ L}$, is a reasonable value for a drug. The language is objective and unambiguous. The problem does not violate any of the invalidity criteria.\n\n### Step 3: Verdict and Action\nThe problem is valid. A complete solution will be provided.\n\n### Solution Derivation\n\nThe analysis proceeds by deriving expressions for the area under the concentration-time curve ($\\mathrm{AUC}$) and systemic clearance ($\\mathrm{CL}$) from their fundamental definitions.\n\n**1. Derivation and Computation of $\\mathrm{AUC}_{0\\to\\infty}$**\n\nThe total area under the concentration-time curve from time $t=0$ to $t=\\infty$, denoted $\\mathrm{AUC}_{0\\to\\infty}$, represents the total exposure to the drug. It is calculated by integrating the plasma concentration function $C(t)$ over this interval.\n\n$$\n\\mathrm{AUC}_{0\\to\\infty} = \\int_{0}^{\\infty} C(t) \\,dt\n$$\n\nSubstituting the given function $C(t) = C_0 \\exp(-k t)$:\n\n$$\n\\mathrm{AUC}_{0\\to\\infty} = \\int_{0}^{\\infty} C_0 \\exp(-k t) \\,dt\n$$\n\nSince $C_0$ is a constant, it can be moved outside the integral:\n\n$$\n\\mathrm{AUC}_{0\\to\\infty} = C_0 \\int_{0}^{\\infty} \\exp(-k t) \\,dt\n$$\n\nThe integral of the exponential function is:\n\n$$\n\\int \\exp(-k t) \\,dt = -\\frac{1}{k} \\exp(-k t)\n$$\n\nEvaluating the definite integral from $0$ to $\\infty$:\n\n$$\n\\mathrm{AUC}_{0\\to\\infty} = C_0 \\left[ -\\frac{1}{k} \\exp(-k t) \\right]_{0}^{\\infty} = C_0 \\left( \\lim_{t\\to\\infty} \\left(-\\frac{1}{k} \\exp(-k t)\\right) - \\left(-\\frac{1}{k} \\exp(-k \\cdot 0)\\right) \\right)\n$$\n\nSince the elimination rate constant $k$ is positive ($k=0.2$ h$^{-1} > 0$), the term $\\exp(-k t)$ approaches $0$ as $t \\to \\infty$. The expression simplifies to:\n\n$$\n\\mathrm{AUC}_{0\\to\\infty} = C_0 \\left( 0 - \\left(-\\frac{1}{k} \\cdot 1\\right) \\right) = \\frac{C_0}{k}\n$$\n\nNow, we substitute the given numerical values: $C_0 = 10$ mg/L and $k = 0.2$ h$^{-1}$.\n\n$$\n\\mathrm{AUC}_{0\\to\\infty} = \\frac{10 \\text{ mg/L}}{0.2 \\text{ h}^{-1}} = 50 \\text{ mg}\\cdot\\text{h/L}\n$$\n\nRounding to four significant figures gives $50.00$ mg$\\cdot$h/L.\n\n**2. Derivation and Computation of Systemic Clearance ($\\mathrm{CL}$)**\n\nSystemic clearance ($\\mathrm{CL}$) is a fundamental pharmacokinetic parameter that describes the volume of plasma cleared of the drug per unit time. It relates the rate of elimination to the plasma concentration. For linear, first-order kinetics, a key relationship derived from mass balance connects the administered dose, clearance, and total exposure.\n\nThe total amount of drug eliminated from the body over all time must equal the bioavailable dose. For an intravenous bolus, the entire dose is bioavailable. The instantaneous rate of elimination is given by $\\mathrm{CL} \\cdot C(t)$. Integrating this rate from $t=0$ to $t=\\infty$ gives the total amount eliminated:\n\n$$\n\\text{Total amount eliminated} = \\int_{0}^{\\infty} (\\text{Rate of elimination}) \\,dt = \\int_{0}^{\\infty} \\mathrm{CL} \\cdot C(t) \\,dt\n$$\n\nSince $\\mathrm{CL}$ is a constant under linear kinetics:\n\n$$\n\\text{Total amount eliminated} = \\mathrm{CL} \\int_{0}^{\\infty} C(t) \\,dt = \\mathrm{CL} \\cdot \\mathrm{AUC}_{0\\to\\infty}\n$$\n\nEquating the total amount eliminated to the administered dose:\n\n$$\n\\text{Dose} = \\mathrm{CL} \\cdot \\mathrm{AUC}_{0\\to\\infty}\n$$\n\nRearranging this equation yields the expression for clearance:\n\n$$\n\\mathrm{CL} = \\frac{\\text{Dose}}{\\mathrm{AUC}_{0\\to\\infty}}\n$$\n\nWe are given the Dose $= 100$ mg and have just calculated $\\mathrm{AUC}_{0\\to\\infty} = 50$ mg$\\cdot$h/L.\n\n$$\n\\mathrm{CL} = \\frac{100 \\text{ mg}}{50 \\text{ mg}\\cdot\\text{h/L}} = 2 \\text{ L/h}\n$$\n\nRounding to four significant figures gives $2.000$ L/h.\n\nIn summary, the total area under the curve is $\\mathrm{AUC}_{0\\to\\infty} = 50.00$ mg$\\cdot$h/L and the systemic clearance is $\\mathrm{CL} = 2.000$ L/h.",
            "answer": "$$\n\\boxed{\\begin{pmatrix} 50.00 & 2.000 \\end{pmatrix}}\n$$"
        },
        {
            "introduction": "A drug's efficacy and safety are governed by its free concentration, which is heavily influenced by plasma protein binding. This practice explores how to quantify the fraction of unbound drug in plasma, $f_u$, a key property that ADMET models aim to predict . By deriving $f_u$ from equilibrium principles and reasoning about its downstream effects on drug distribution and clearance, you will gain a deeper appreciation for how molecular interactions shape whole-body pharmacokinetics.",
            "id": "3835215",
            "problem": "In building Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) property prediction models, plasma protein binding strongly modulates the fraction unbound in plasma, denoted $f_u$, which in turn influences both the apparent volume of distribution and clearance. Consider a neutral small molecule drug that binds reversibly to human serum albumin according to the equilibrium $D + P \\rightleftharpoons DP$, where $D$ is free drug, $P$ is free protein, and $DP$ is the drug–protein complex. The dissociation constant is defined by the law of mass action as $K_d = \\frac{[D][P]}{[DP]}$. Assume a single equivalent high-affinity binding site per protein monomer, independent binding, and that the drug is at trace concentration relative to protein such that protein saturation is negligible. The total protein concentration is $[P]_{\\mathrm{tot}} = 600\\,\\mu\\mathrm{M}$ (albumin) and the dissociation constant is $K_d = 1\\,\\mu\\mathrm{M}$.\n\nStarting only from the definition of $K_d$ and conservation of mass for drug and protein, and invoking the stated dilute-drug assumption to simplify where justified, derive an expression for the fraction unbound $f_u$ in terms of $K_d$ and $[P]_{\\mathrm{tot}}$ under these conditions. Then evaluate $f_u$ numerically for the given values. Round your numerical result to four significant figures and express it as a unitless decimal.\n\nFinally, using as foundational facts the standard qualitative behavior of the well-stirred hepatic model of clearance and the typical partitioning relationship between plasma and tissues in distribution equilibrium, briefly justify how such a low $f_u$ would impact the apparent steady-state volume of distribution $V_{ss}$ and hepatic clearance $CL_h$ in the limits where $f_u \\cdot CL_{\\mathrm{int}} \\ll Q_h$ and $f_u \\cdot CL_{\\mathrm{int}} \\gg Q_h$, where $CL_{\\mathrm{int}}$ is intrinsic clearance and $Q_h$ is hepatic blood flow. Do not compute $V_{ss}$ or $CL_h$ numerically; provide only the qualitative directionality in your reasoning.",
            "solution": "The problem statement has been validated and is deemed sound. It is scientifically grounded in the principles of chemical equilibrium and pharmacokinetics, is well-posed with sufficient and consistent information, and is expressed in objective, formal language. We may therefore proceed with the solution.\n\nThe problem requires a three-part response: first, the derivation of an expression for the fraction of unbound drug in plasma, $f_u$; second, the numerical evaluation of $f_u$ given specific parameters; and third, a qualitative analysis of the impact of this $f_u$ value on the apparent volume of distribution and hepatic clearance.\n\n**Part 1: Derivation of the expression for $f_u$**\n\nThe fraction unbound, $f_u$, is defined as the ratio of the concentration of free drug, $[D]$, to the total concentration of drug in plasma, $[D]_{\\mathrm{tot}}$.\n$$f_u = \\frac{[D]}{[D]_{\\mathrm{tot}}}$$\nThe total drug concentration is the sum of the free drug concentration, $[D]$, and the concentration of the drug-protein complex, $[DP]$.\n$$[D]_{\\mathrm{tot}} = [D] + [DP]$$\nSubstituting this into the definition of $f_u$ gives:\n$$f_u = \\frac{[D]}{[D] + [DP]}$$\nThe problem provides the definition for the dissociation constant, $K_d$, based on the law of mass action for the equilibrium $D + P \\rightleftharpoons DP$:\n$$K_d = \\frac{[D][P]}{[DP]}$$\nWe can rearrange this expression to solve for $[DP]$:\n$$[DP] = \\frac{[D][P]}{K_d}$$\nNow, we substitute this expression for $[DP]$ into the equation for $f_u$:\n$$f_u = \\frac{[D]}{[D] + \\frac{[D][P]}{K_d}}$$\nThe term $[D]$ can be factored out from the denominator:\n$$f_u = \\frac{[D]}{[D] \\left(1 + \\frac{[P]}{K_d}\\right)}$$\nAssuming $[D] \\neq 0$, we can cancel this term from the numerator and denominator, yielding:\n$$f_u = \\frac{1}{1 + \\frac{[P]}{K_d}}$$\nThis expression for $f_u$ depends on the free protein concentration, $[P]$. We are given the total protein concentration, $[P]_{\\mathrm{tot}}$. The conservation of mass for the protein dictates that the total protein concentration is the sum of the free protein concentration, $[P]$, and the concentration of protein bound in the drug-protein complex, $[DP]$.\n$$[P]_{\\mathrm{tot}} = [P] + [DP]$$\nThe problem states the critical assumption that the drug is present at a trace concentration relative to the protein, meaning its total concentration is negligible compared to the total protein concentration: $[D]_{\\mathrm{tot}} \\ll [P]_{\\mathrm{tot}}$. Since each drug-protein complex contains one molecule of drug, the concentration of the complex cannot exceed the total drug concentration, i.e., $[DP] \\le [D]_{\\mathrm{tot}}$. Therefore, it follows directly from the assumption that $[DP] \\ll [P]_{\\mathrm{tot}}$.\n\nGiven this, in the mass balance equation for the protein, $[P]_{\\mathrm{tot}} = [P] + [DP]$, the term $[DP]$ is negligible compared to $[P]_{\\mathrm{tot}}$, which allows for the approximation:\n$$[P] \\approx [P]_{\\mathrm{tot}}$$\nSubstituting this approximation into our expression for $f_u$ gives the final desired relationship under the specified dilute-drug conditions:\n$$f_u = \\frac{1}{1 + \\frac{[P]_{\\mathrm{tot}}}{K_d}}$$\n\n**Part 2: Numerical Evaluation of $f_u$**\n\nWe are given the total protein concentration $[P]_{\\mathrm{tot}} = 600\\,\\mu\\mathrm{M}$ and the dissociation constant $K_d = 1\\,\\mu\\mathrm{M}$. Substituting these values into the derived expression:\n$$f_u = \\frac{1}{1 + \\frac{600\\,\\mu\\mathrm{M}}{1\\,\\mu\\mathrm{M}}}$$\nThe units of molarity ($\\mu\\mathrm{M}$) cancel, as expected for a unitless fraction:\n$$f_u = \\frac{1}{1 + 600} = \\frac{1}{601}$$\nTo evaluate this numerically and round to four significant figures:\n$$f_u \\approx 0.00166389...$$\nRounding to four significant figures gives:\n$$f_u \\approx 0.001664$$\n\n**Part 3: Qualitative Impact on $V_{ss}$ and $CL_h$**\n\nThe calculated value of $f_u \\approx 0.001664$ is very low, indicating that over $99.8\\%$ of the drug in plasma is bound to protein. We now analyze the consequences for the steady-state volume of distribution, $V_{ss}$, and hepatic clearance, $CL_h$.\n\n*   **Impact on Apparent Volume of Distribution ($V_{ss}$):**\n    The apparent volume of distribution at steady state, $V_{ss}$, relates the total amount of drug in the body to the plasma concentration. Its fundamental relationship to protein and tissue binding is given by the equation $V_{ss} = V_p + V_t \\frac{f_u}{f_{u,t}}$, where $V_p$ is a composite plasma volume, $V_t$ is a composite tissue volume, and $f_{u,t}$ is the fraction unbound in tissue. This equation shows that $V_{ss}$ is directly proportional to $f_u$. Only unbound drug is free to cross biological membranes and distribute from the plasma into tissues. A very low $f_u$ signifies extensive binding to plasma proteins, which effectively sequesters the drug within the vascular compartment. Consequently, a low $f_u$ severely restricts the drug's ability to distribute into tissues, leading to a **smaller** apparent volume of distribution, $V_{ss}$, assuming tissue binding ($f_{u,t}$) is not altered.\n\n*   **Impact on Hepatic Clearance ($CL_h$):**\n    According to the well-stirred model of hepatic clearance, $CL_h$ is given by:\n    $$CL_h = \\frac{Q_h \\cdot f_u \\cdot CL_{\\mathrm{int}}}{Q_h + f_u \\cdot CL_{\\mathrm{int}}}$$\n    Here, $Q_h$ is the hepatic blood flow and $CL_{\\mathrm{int}}$ is the intrinsic clearance (the metabolic capacity of the liver enzymes for unbound drug). The impact of a low $f_u$ depends on the magnitude of the drug's unbound intrinsic clearance, $f_u \\cdot CL_{\\mathrm{int}}$, relative to hepatic blood flow, $Q_h$.\n\n    1.  **Case 1: $f_u \\cdot CL_{\\mathrm{int}} \\ll Q_h$ (Low Extraction Ratio Drug).**\n        In this limit, the term $f_u \\cdot CL_{\\mathrm{int}}$ in the denominator is negligible compared to $Q_h$. The expression for clearance simplifies to:\n        $$CL_h \\approx \\frac{Q_h \\cdot f_u \\cdot CL_{\\mathrm{int}}}{Q_h} = f_u \\cdot CL_{\\mathrm{int}}$$\n        This situation is termed \"capacity-limited\" or \"binding-sensitive\" clearance. The clearance rate is directly proportional to both the fraction unbound ($f_u$) and the intrinsic metabolic capacity ($CL_{\\mathrm{int}}$). Since $f_u$ is very low, hepatic clearance $CL_h$ will also be **low**. The rate-limiting factor is the small concentration of free drug available to the metabolizing enzymes.\n\n    2.  **Case 2: $f_u \\cdot CL_{\\mathrm{int}} \\gg Q_h$ (High Extraction Ratio Drug).**\n        In this limit, the term $Q_h$ in the denominator is negligible compared to $f_u \\cdot CL_{\\mathrm{int}}$. The expression simplifies to:\n        $$CL_h \\approx \\frac{Q_h \\cdot f_u \\cdot CL_{\\mathrm{int}}}{f_u \\cdot CL_{\\mathrm{int}}} = Q_h$$\n        This situation is termed \"perfusion-limited\" or \"flow-dependent\" clearance. Clearance becomes independent of both protein binding ($f_u$) and intrinsic clearance ($CL_{\\mathrm{int}}$), and is approximately equal to the hepatic blood flow. For such a drug, even though $f_u$ is very low, the intrinsic clearance $CL_{\\mathrm{int}}$ is so high that the liver is extremely efficient at metabolism. It can effectively strip drug molecules from albumin as they transit through the liver, clearing nearly all drug delivered by the blood in a single pass. Therefore, the rate-limiting factor is the rate of delivery of drug to the liver, which is the blood flow $Q_h$. In this scenario, despite a very low $f_u$, the hepatic clearance $CL_h$ would be **high**.",
            "answer": "$$\\boxed{0.001664}$$"
        },
        {
            "introduction": "A predictive model's output is only trustworthy for molecules that are chemically similar to its training data. This exercise introduces the critical concept of the applicability domain, which defines the boundaries of a model's reliability . You will use the Tanimoto similarity coefficient, a standard metric in cheminformatics, to quantitatively assess whether a new molecule falls within a model's domain, a cornerstone of responsible model application.",
            "id": "3835275",
            "problem": "Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) property prediction models often rely on applicability domain assessments based on chemical similarity in the space of Extended-Connectivity Fingerprints (ECFP). Consider a binary ECFP representation with $p=1024$ bits, where each molecule is represented by the set of activated fingerprint indices. Let a query molecule $Q$ have $|Q|=72$ activated bits. A training corpus $\\mathcal{T}$ contains $5$ molecules $\\{M_1, M_2, M_3, M_4, M_5\\}$ with activated bit counts and pairwise overlaps with $Q$ as follows:\n- $|M_1|=64$, and $|Q \\cap M_1|=22$.\n- $|M_2|=85$, and $|Q \\cap M_2|=27$.\n- $|M_3|=70$, and $|Q \\cap M_3|=30$.\n- $|M_4|=78$, and $|Q \\cap M_4|=33$.\n- $|M_5|=76$, and $|Q \\cap M_5|=34$.\n\nUsing the standard set-theoretic definition of similarity on binary fingerprints, compute the nearest-neighbor Tanimoto similarity between $Q$ and the training set $\\mathcal{T}$, and, based on a predefined applicability domain threshold $t_{\\mathrm{dom}}=0.35$, decide whether $Q$ is out-of-domain for the model. Report only the nearest-neighbor similarity value, rounded to four significant figures. Express your answer as a unitless decimal.",
            "solution": "The problem requires the calculation of the nearest-neighbor Tanimoto similarity for a query molecule $Q$ with respect to a training set $\\mathcal{T}$ of five molecules, represented by Extended-Connectivity Fingerprints (ECFP). The applicability domain of the underlying model is then assessed based on this similarity.\n\nFirst, the Tanimoto similarity coefficient, $T_c$, for two molecules $A$ and $B$, represented as sets of activated fingerprint bits, is defined by the standard set-theoretic formula:\n$$T_c(A, B) = \\frac{|A \\cap B|}{|A \\cup B|}$$\nwhere $|A \\cap B|$ is the number of bits activated in both molecules (the size of the intersection of the sets) and $|A \\cup B|$ is the number of bits activated in at least one of the two molecules (the size of the union of the sets). The size of the union can be expressed using the principle of inclusion-exclusion:\n$$|A \\cup B| = |A| + |B| - |A \\cap B|$$\nSubstituting this into the Tanimoto coefficient formula gives the form used for calculation:\n$$T_c(A, B) = \\frac{|A \\cap B|}{|A| + |B| - |A \\cap B|}$$\nThe dimension of the fingerprint space, $p=1024$, is not required for this calculation, which depends only on the counts of activated bits.\n\nThe givens for the query molecule $Q$ and the training set $\\mathcal{T} = \\{M_1, M_2, M_3, M_4, M_5\\}$ are:\n- $|Q| = 72$\n- For $M_1$: $|M_1| = 64$, $|Q \\cap M_1| = 22$\n- For $M_2$: $|M_2| = 85$, $|Q \\cap M_2| = 27$\n- For $M_3$: $|M_3| = 70$, $|Q \\cap M_3| = 30$\n- For $M_4$: $|M_4| = 78$, $|Q \\cap M_4| = 33$\n- For $M_5$: $|M_5| = 76$, $|Q \\cap M_5| = 34$\n\nWe now compute the Tanimoto similarity between $Q$ and each molecule $M_i$ in $\\mathcal{T}$.\n\nFor $M_1$:\n$$T_c(Q, M_1) = \\frac{|Q \\cap M_1|}{|Q| + |M_1| - |Q \\cap M_1|} = \\frac{22}{72 + 64 - 22} = \\frac{22}{114} \\approx 0.19298$$\n\nFor $M_2$:\n$$T_c(Q, M_2) = \\frac{|Q \\cap M_2|}{|Q| + |M_2| - |Q \\cap M_2|} = \\frac{27}{72 + 85 - 27} = \\frac{27}{130} \\approx 0.20769$$\n\nFor $M_3$:\n$$T_c(Q, M_3) = \\frac{|Q \\cap M_3|}{|Q| + |M_3| - |Q \\cap M_3|} = \\frac{30}{72 + 70 - 30} = \\frac{30}{112} \\approx 0.26786$$\n\nFor $M_4$:\n$$T_c(Q, M_4) = \\frac{|Q \\cap M_4|}{|Q| + |M_4| - |Q \\cap M_4|} = \\frac{33}{72 + 78 - 33} = \\frac{33}{117} \\approx 0.28205$$\n\nFor $M_5$:\n$$T_c(Q, M_5) = \\frac{|Q \\cap M_5|}{|Q| + |M_5| - |Q \\cap M_5|} = \\frac{34}{72 + 76 - 34} = \\frac{34}{114} \\approx 0.29825$$\n\nThe set of similarity values is $\\{0.19298, 0.20769, 0.26786, 0.28205, 0.29825\\}$. The nearest-neighbor similarity is the maximum value in this set.\n$$\\max(\\{T_c(Q, M_i)\\}_{i=1}^5) = T_c(Q, M_5) \\approx 0.29825$$\n\nThe problem requires a decision on the applicability domain based on the threshold $t_{\\mathrm{dom}}=0.35$. A molecule is considered out-of-domain if its similarity to all training set members is below this threshold. In this case, the nearest-neighbor (maximum) similarity is approximately $0.298$, which is less than $t_{\\mathrm{dom}}=0.35$.\n$$0.298 < 0.35$$\nTherefore, the query molecule $Q$ is considered to be out-of-domain for the model.\n\nThe final step is to report the nearest-neighbor similarity value rounded to four significant figures.\nThe nearest-neighbor similarity is $T_c(Q, M_5) = \\frac{34}{114} \\approx 0.2982456...$.\nRounding this value to four significant figures gives $0.2982$.",
            "answer": "$$\\boxed{0.2982}$$"
        }
    ]
}